Evaluation of efficacy and nephrotoxicity during vancomycin therapy: A retrospective study in China

Wang,Liping; Yuan,Qing; Tan,Min; Xie,Shuanshuan; Wu,Jufang; Song,Xiaolian; Wang,Changhui

doi:10.3892/etm.2019.7188

Evaluation of efficacy and nephrotoxicity during vancomycin therapy: A retrospective study in China

Authors:
- Liping Wang
- Qing Yuan
- Min Tan
- Shuanshuan Xie
- Jufang Wu
- Xiaolian Song
- Changhui Wang
View Affiliations

Affiliations: Department of Respiratory Medicine, Shanghai 10th People's Hospital, Tongji University, Shanghai 200072, P.R. China, Department of Emergency Medicine, Shanghai 10th People's Hospital, Tongji University, Shanghai 200072, P.R. China, Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: January 21, 2019 https://doi.org/10.3892/etm.2019.7188
Pages: 2389-2396

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the predictive value of vancomycin serum concentrations regarding its efficacy and nephrotoxicity in a Chinese population and to determine a relatively safe optimal target concentration during vancomycin therapy. A total of 65 patients that received vancomycin between March 2013 and March 2018 at Shanghai 10th People's Hospital (Shanghai, China) were enrolled and their vancomycin trough and peak concentrations were monitored. Factor analysis was performed in order to exclude interaction between variables. Univariate and multivariate analyses were used to identify predictors of drug efficacy and nephrotoxicity. Receiver operating characteristic curve analysis was performed to determine the thresholds of the vancomycin trough and peak concentrations for optimal efficacy and acceptable nephrotoxicity, respectively. Among the 65 cases, treatment was deemed to be effective for 43 patients and ineffective for 22 patients. Furthermore, 20 patients fulfilled the criteria for nephrotoxicity. A total of 15 continuous variables loaded the first five factors by factor analysis (which converts large numbers of highly inter‑correlated variables into a small number of comprehensive indicators that reflect a dimensionality reduction) and the factors were as follows: Inflammation, renal function, liver function, vancomycin trough and peak concentrations, and nutritional status. Univariate and multivariate analyses identified the trough concentration and peak concentration as independent variables associated with efficacy and nephrotoxicity of vancomycin, and the nutritional status was a risk factor associated with efficacy. Regarding efficacy, the critical values for the trough concentration and peak concentration were determined to be 9.02 mg/l (95.3% sensitivity and 68.2% specificity) and 23.62 mg/l (83.7% sensitivity and 59.1% specificity), respectively. The thresholds of vancomycin trough and peak concentrations for the development of nephrotoxicity were 16.08 mg/l (80.0% sensitivity and 84.4% specificity) and 30.42 mg/l (75.0% sensitivity and 73.3% specificity), respectively. In conclusion, during vancomycin therapy, the trough and peak concentrations are associated with efficacy and nephrotoxicity. Furthermore, a trough concentration between 9.02 and 16.08 mg/l and a peak concentration of 23.62‑30.42 mg/l were determined to be relatively safe (the clinical trial registry no. ChiCTR‑OPC‑16007920).

View Figures

View References

1	National Nosocomial Infections Surveillance System: National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 32:470–485. 2004. View Article : Google Scholar : PubMed/NCBI
2	Haque NZ, Zuniga LC, Peyrani P, Reyes K, Lamerato L, Moore CL, Patel S, Allen M, Peterson E, Wiemken T, et al: Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest. 138:1356–1362. 2010. View Article : Google Scholar : PubMed/NCBI
3	Martin JH, Norris R, Barras M, Roberts J, Morris R, Doogue M and Jones RD G: Therapeutic monitoring of vancomycinin adult patients: A consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Clin Biochem Rev. 31:21–24. 2010.PubMed/NCBI
4	Moellering RC Jr: Vancomycin: A 50-year reassessment. Clin Infect Dis. 42 Suppl 1:S3–S4. 2006. View Article : Google Scholar : PubMed/NCBI
5	Stevens DL: The role of vancomycin in the treatment paradigm. Clin Infect Dis. 42 Suppl 1:S51–S57. 2006. View Article : Google Scholar : PubMed/NCBI
6	Shah-Khan F, Scheetz MH and Ghossein C: Biopsy-proven acute tubular necrosis due to vancomycin toxicity. Int J Nephrol. 2011:4368562001.
7	Htike NL, Santoro J, Gilbert B, Elfenbein IB and Teehan G: Biopsy-proven vancomycin-associated interstitial nephritis and acute tubular necrosis. Clin Exp Nephrol. 16:320–324. 2012. View Article : Google Scholar : PubMed/NCBI
8	Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, et al: Practice guidelines for therapeutic drug monitoring of vancomycin: A consensus review of the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring. J Infect Chemother. 19:365–380. 2013. View Article : Google Scholar : PubMed/NCBI
9	Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR and Levine DP: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 66:82–98. 2009. View Article : Google Scholar : PubMed/NCBI
10	Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr and Eliopoulos GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 42:2398–2402. 2004. View Article : Google Scholar : PubMed/NCBI
11	Xin HW, Tong HY, Dong QR, Li Q, Wu XC, Yu AR, Xiong L and Li WL: Monitoring of blood concentration and individualized administration of vancomycin and norvancomycin in 207 cases. Chin J Pharmacoepidemiol. 21:166–169. 2012.(In Chinese).
12	Chen CY, Zhu SY, Zhou KT, Zhao YY and Xu P: Retrospective analysis of nephrotoxicity and efficacy of vancomycin trough concentrations in patients with severe pneumonia. Chin J Mod Appl Pharm Pharm Mod Appl Pharm. 33:1188–1194. 2016.(In Chinese).
13	Cockcroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 16:31–41. 1976. View Article : Google Scholar : PubMed/NCBI
14	Galbraith JI, Moustaki I, Bartholomew DJ and Steele F: The analysis and interpretation of multivariate data for social scientists. Chapman and Hall/CRC. 56:2802002.
15	Jolliffe IT: Principal Component Analysis. Springer. (New York, NY). 1986. View Article : Google Scholar
16	Levine DP: Vancomycin: A history. Clin Infect Dis. 42 Suppl 1:S5–S12. 2006. View Article : Google Scholar : PubMed/NCBI
17	Matzke GR, Zhanel GG and Guay DR: Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 11:257–282. 1986. View Article : Google Scholar : PubMed/NCBI
18	Nakamura T, Takano M, Yasuhara M and Inui K: In-vivo clearance study of vancomycin in rats. J Pharm Pharmacol. 48:1197–1200. 1996. View Article : Google Scholar : PubMed/NCBI
19	Dieterich C, Puey A, Lin S, Swezey R, Furimsky A, Fairchild D, Mirsalis JC and Ng HH: Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol Sci. 107:258–269. 2009. View Article : Google Scholar : PubMed/NCBI
20	Nishino Y, Takemura S, Minamiyama Y, Hirohashi K, Ogino T, Inoue M, Okada S and Kinoshita H: Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic Res. 37:373–379. 2003. View Article : Google Scholar : PubMed/NCBI
21	Oktem F, Arslan MK, Ozguner F, Candir O, Yilmaz HR, Ciris M and Uz E: In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: Protection by erdosteine. Toxicology. 215:227–233. 2005. View Article : Google Scholar : PubMed/NCBI
22	Hong S, Valderrama E, Mattana J, Shah HH, Wagner JD, Esposito M and Singhal PC: Vancomycin-induced acute granulomatous interstitial nephritis: Therapeutic options. Am J Med Sci. 334:296–300. 2007. View Article : Google Scholar : PubMed/NCBI
23	Lodise TP, Patel N, Lomaestro BM, Rodvold KA and Drusano GL: Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 49:507–514. 2009. View Article : Google Scholar : PubMed/NCBI
24	Wong-Beringer A, Joo J, Tse E and Beringer P: Vancomycin-associated nephrotoxicity: A critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 37:95–101. 2011. View Article : Google Scholar : PubMed/NCBI
25	Suzuki Y, Kawasaki K, Sato Y, Tokimatsu I, Itoh H, Hiramatsu K, Takeyama M and Kadota J: Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia. Chemotherapy. 58:308–312. 2012. View Article : Google Scholar : PubMed/NCBI
26	Iwamoto T, Kagawa Y and Kojima M: Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull. 26:876–879. 2003. View Article : Google Scholar : PubMed/NCBI
27	Jeffres MN, Isakow W, Doherty JA, Micek ST and Kollef MH: A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 29:1107–1115. 2007. View Article : Google Scholar : PubMed/NCBI
28	Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J and Mauldin PD: Relationship between vancomycin trough concentrations and nephrotoxicity: A prospective multicenter trial. Antimicrob Agents Chemother. 55:5475–5479. 2011. View Article : Google Scholar : PubMed/NCBI
29	Liu Y, Yin Y, Liu XZ, Yao HJ, Li LX, Chen JH, Chen T, Lu XT, Bu SH and Zhang J: Retrospective analysis of vancomycin nephrotoxicity in elderly chinese patients. Pharmacology. 95:279–284. 2015. View Article : Google Scholar : PubMed/NCBI
30	Han HK, An H, Shin KH, Shin D, Lee SH, Kim JH, Cho SH, Kang HR, Jang IJ, Yu KS and Lim KS: Trough concentration over 12.1 mg/l is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring. Ther Drug Monit. 36:606–611. 2014. View Article : Google Scholar : PubMed/NCBI